Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sample CME manuscript submission: Response to the article by Pham et al entitled "Review BRAF inhibition and the spectrum of granulomatous reactions".
Marcaillou M, Dion J, Baroudjian B, Ezrine E, Carrera C, Anderle A, Apalla Z, Freites-Martinez A, Pages C, Lebbe C, Meyer N, Sibaud V, Comont T. Marcaillou M, et al. Among authors: freites martinez a. J Am Acad Dermatol. 2022 Aug;87(2):e85-e88. doi: 10.1016/j.jaad.2022.04.053. Epub 2022 May 5. J Am Acad Dermatol. 2022. PMID: 35526651 No abstract available.
European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V. Apalla Z, et al. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):332-350. doi: 10.1111/jdv.17855. Epub 2021 Dec 15. J Eur Acad Dermatol Venereol. 2022. PMID: 34910332
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V. Nikolaou VA, et al. Among authors: freites martinez a. Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6. Br J Dermatol. 2022. PMID: 35861701
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study.
Freites-Martinez A, Nikolaou V, Lallas K, Carrera C, Sollena P, Apalla Z, Starace M, Fattore D, Fabbrocini G, Segura S, Riganti J, Sibaud V. Freites-Martinez A, et al. J Am Acad Dermatol. 2023 Mar;88(3):718-720. doi: 10.1016/j.jaad.2022.08.063. Epub 2022 Sep 22. J Am Acad Dermatol. 2023. PMID: 36152697 No abstract available.
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, Caro G, Freites-Martinez A, Hirner JP, Markova A, McLellan BN, Rossi A, Sauder MB, Seminario-Vidal L, Sibaud V, Owen DH, Dulmage BO, Chen ST, Kaffenberger BH. Mital R, et al. Among authors: freites martinez a. Int J Dermatol. 2023 Aug;62(8):1020-1025. doi: 10.1111/ijd.16714. Epub 2023 May 19. Int J Dermatol. 2023. PMID: 37203799
Supportive oncodermatology practices in Europe and the USA.
Freites-Martinez A, Apalla Z, Fattore D, Fida M, Bang AS, Smith J, Babakoohi S, Lacouture M, Sibaud V. Freites-Martinez A, et al. J Eur Acad Dermatol Venereol. 2024 May;38(5):e440-e443. doi: 10.1111/jdv.19679. Epub 2023 Dec 6. J Eur Acad Dermatol Venereol. 2024. PMID: 38058268 No abstract available.
44 results